ONC.TO - Oncolytics Biotech Inc.

Toronto - Toronto Delayed Price. Currency in CAD
2.6700
0.0000 (0.00%)
At close: 3:59PM EST
Stock chart is not supported by your current browser
Previous Close2.6700
Open2.7000
Bid2.61 x 0
Ask2.75 x 0
Day's Range2.6000 - 2.7100
52 Week Range2.2600 - 10.6500
Volume22,530
Avg. Volume28,128
Market Cap46.457M
Beta (3Y Monthly)2.84
PE Ratio (TTM)N/A
EPS (TTM)-1.10
Earnings DateMay 4, 2017 - May 8, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est11.75
  • ACCESSWIRE6 days ago

    Oncolytics Biotech(R) Announces Spanish Regulatory Approval of AWARE-1 Window of Opportunity Study in Breast Cancer

    CALGARY, AB and SAN DIEGO, CA / ACCESSWIRE / February 11, 2019 / Oncolytics Biotech® Inc. (ONCY) (ONC.TO), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced that the Spanish Agency for Medicine and Health Products has granted final approval for the forthcoming AWARE-1 window of opportunity study in breast cancer. This study, which represents the first application of Oncolytics' master clinical supply agreement with Roche for the combination of pelareorep with a leading immune checkpoint inhibitor atezolizumab (Tecentriq®), is a precursor to Oncolytics' previously announced phase 3 breast cancer study and will add to the company's growing critical mass of biomarker data.

  • ACCESSWIRE13 days ago

    Oncolytics Biotech(R) to Present at the 21st Annual BIO CEO & Investor Conference

    CALGARY, AB and SAN DIEGO, CA / ACCESSWIRE / February 4, 2019 / Oncolytics Biotech® Inc. (ONCY) (ONC.TO), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced that it would present at the 21st Annual BIO CEO & Investor Conference. The presentation, by Dr. Matt Coffey, President & CEO of Oncolytics, will take place at 2:30 pm ET, on Monday, February 11, 2019, in the Herald/Soho Room at the New York Marriott Marquis. A live audio link to the webcast session will be available on the Company's website at http://www.oncolyticsbiotech.com/investor-centre/presentations.

  • ACCESSWIRE20 days ago

    Today's Research Reports on Oncolytics Biotech, Delivra, Aptose Biosciences and ProMIS Neurosciences

    NEW YORK, NY / ACCESSWIRE / January 28, 2019 / The Market Wealth Report strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register ...

  • GlobeNewswire2 months ago

    Oncolytics Biotech® Announces First Patient Treated in Study Combining Pelareorep, Carfilzomib and the Checkpoint Inhibitor Opdivo® in Multiple Myeloma

    Oncolytics Biotech® Inc. (ONCY) (ONC.TO), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced that the first patient was treated in a phase 1 dose escalation study combining pelareorep and carfilzomib with Bristol-Myers Squibb’s checkpoint inhibitor Opdivo® (nivolumab) to treat relapsed multiple myeloma patients. This study is based on findings from the NCI 9603 multiple myeloma study that combined pelareorep with carfilzomib that resulted in objective responses, elimination of multiple myeloma cells and most importantly, an inflamed phenotype with PD-L1 overexpression. “Having worked with pelareorep in multiple myeloma and understanding its ability to act as a potentiator of checkpoint blockade, I’m very excited to work with the Oncolytics team on this study,” said Dr. Craig Hofmeister, Associate Professor, Department of Hematology and Medical Oncology Emory University School of Medicine.

  • ACCESSWIRE2 months ago

    Today's Research Reports on IntelliPharmaCeutics International, Centric Health, Knight Therapeutics and Oncolytics Biotech

    NEW YORK, NY / ACCESSWIRE / December 11, 2018 / The Market Edge strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us ...

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of ONC.TO earnings conference call or presentation 12-Nov-18 1:30pm GMT

    Q3 2018 Oncolytics Biotech Inc Earnings Call

  • GlobeNewswire2 months ago

    Oncolytics Biotech® Announces Increased PD-L1 Expression When Combining Pelareorep with a Proteasome Inhibitor in Poster Presentation at the 60th American Society of Hematology Annual Meeting & Exposition

    Oncolytics Biotech® Inc. (ONCY) (ONC.TO), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced a poster presentation made at the American Society of Hematology (ASH) Annual Meeting & Exposition taking place December 1-4 in San Diego, California.  The poster highlights pelareorep’s ability to increase PD-L1 expression on tumor cells in patients with relapsed myeloma. The poster, authored by Craig C. Hofmeister, Acting Associate Professor, Department of Hematology and Medical Oncology Emory University School of Medicine, et al., is titled “Oncolytics Virus Replication Using Pelareorep and Carfilzomib in Relapsed Myeloma Patients Increases PD-L1 Expression with Clinical Responses”, was presented yesterday.

  • GlobeNewswire3 months ago

    Oncolytics Biotech® Announces Appointment of Rita Laeufle, M.D., as Chief Medical Officer

    Oncolytics Biotech® Inc. (ONCY) (ONC.TO), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced that Dr. Rita Laeufle, M.D., Ph.D., who has been working as a consultant for Oncolytics for the last four months, has been appointed as Chief Medical Officer.  Dr. Laeufle will oversee the clinical development plan for pelareorep as the company drives towards a registration study in breast cancer. “Dr. Laeufle brings a tremendous track record in clinical advancement to Oncolytics, including an approval in the treatment of metastatic breast cancer,” said Dr. Matt Coffey, President and Chief Executive Officer of Oncolytics Biotech.

  • Benzinga3 months ago

    The Daily Biotech Pulse: Abeona Fires CEO, Loxo Passes FDA Muster, Bristol-Myers Flunks Lung Cancer Trial

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Nov. 26) Emergent Biosolutions Inc (NYSE: EBS ) Vericel Corp ...

  • GlobeNewswire3 months ago

    Oncolytics Biotech® Announces First Patient Treated in Phase 2 Study Combining Pelareorep and Keytruda® in Advanced Pancreatic Cancer

    Oncolytics Biotech® Inc. (ONCY) (ONC.TO), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced that the first patient was treated in a phase 2 study combining pelareorep with Merck’s Keytruda® to treat advanced pancreatic adenocarcinoma. “We are very excited to start enrollment in this combination study which expands upon our findings from an earlier Keytruda study in advanced pancreatic cancer,” said Dr. Matt Coffey, President and Chief Executive Officer of Oncolytics Biotech. “REO 024, our previous phase 1b study with Keytruda, showed objective response, long-term stabilization of disease and promotion of an inflamed phenotype in second line pancreatic cancer patients.

  • ACCESSWIRE4 months ago

    Today's Research Reports on ESSA Pharma, Oncolytics Biotech, Aptose Biosciences and OrganiGram

    NEW YORK, NY / ACCESSWIRE / October 5, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register ...

  • ACCESSWIRE5 months ago

    Today's Research Reports on Aralez Pharmaceuticals, OrganiGram Holdings, Oncolytics Biotech and Aptose Biosciences

    NEW YORK, NY / ACCESSWIRE / September 10, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register ...